liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia
Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
Department of Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden.
Kröber, A., Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Show others and affiliations
2006 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 20, no 1, 77-81 p.Article in journal (Refereed) Published
Abstract [en]

The G(-248)A polymorphism in the promoter region of the Bax gene was recently associated with low Bax expression, more advanced stage, treatment resistance and short overall survival in B-cell chronic lymphocytic leukemia (CLL), the latter particularly in treated patients. To investigate this further, we analyzed 463 CLL patients regarding the presence or absence of the G(-248)A polymorphism and correlated with overall survival, treatment status and known prognostic factors, for example, Binet stage, VH mutation status and genomic aberrations. In this material, similar allele and genotype frequencies of the Bax polymorphism were demonstrated in CLL patients and controls (n=207), where 19 and 21% carried this polymorphism, respectively, and no skewed distribution of the polymorphism was evident between different Binet stages and VH mutated and unmutated CLLs. Furthermore, no difference in overall survival was shown between patients displaying the G(-248)A polymorphism or not (median survival 85 and 102 months, respectively, P=0.21), and the polymorphism did not influence outcome specifically in treated CLL. Neither did the polymorphism affect outcome in prognostic subsets defined by VH mutation status or genomic aberrations. In conclusion, the pathogenic role and clinical impact of the Bax polymorphism is limited in CLL. © 2006 Nature Publishing Group All rights reserved.

Place, publisher, year, edition, pages
2006. Vol. 20, no 1, 77-81 p.
Keyword [en]
Bax promoter polymorphism, Binet stage, Chronic lymphocytic leukemia, Genomic aberrations, Immunoglobulin VH gene mutation status, Prognosis
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:liu:diva-50316DOI: 10.1038/sj.leu.2404030OAI: oai:DiVA.org:liu-50316DiVA: diva2:271212
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-12

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Haematology UHL
In the same journal
Leukemia
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 42 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf